"In our study, we found that xenon gas has the capability of reducing memories of traumatic events," said Edward G Meloni, assistant psychologist at McLean Hospital and an assistant professor of Psychiatry at Harvard Medical School.
"It's an exciting breakthrough, as this has the potential to be a new treatment for individuals suffering from PTSD," said Meloni.
In the study, Meloni and Marc J Kaufman, director of the McLean Hospital Translational Imaging Laboratory, examined whether a low concentration of xenon gas could interfere with a process called reconsolidation - a state in which reactivated memories become susceptible to modification.
The investigators used an animal model of PTSD called fear-conditioning to train rats to be afraid of environmental cues that were paired with brief footshocks.
Also Read
Reactivating the fearful memory was done by exposing the rats to those same cues and measuring their freezing response as a readout of fear.
Meloni points out that the inherent properties of a gas such as xenon make it especially attractive for targeting dynamic processes such as memory reconsolidation.
"Unlike other drugs or medications that may also block NMDA receptors involved in memory, xenon gets in and out of the brain very quickly.
"The fact that we were able to inhibit remembering of a traumatic memory with xenon is very promising because it is currently used in humans for other purposes, and thus it could be repurposed to treat PTSD," added Kaufman.
The study was published in the journal PLOS ONE.